K-Line Chart, actual market data is subject to the trading page.
Key Data
Prev. Open
$5.33
Prev. Close
$6.20
Prev. Day's Range
$5.20 - $6.63
52W Range
$4.35 - $14.00
Trading Volume
5.848M
MC
$641.991M
P/E Ratio
--
EPS
$-1.46
Company Overview
NASDAQ
Candel Therapeutics Inc. is an innovative biotechnology firm dedicated to advancing cancer treatment through its proprietary oncolytic virus technology, which selectively targets malignant cells while sparing healthy tissue. The company boasts a robust pipeline that encompasses multiple hard-to-treat cancers, enhancing anti-tumor immunity and aiming to provide significant therapeutic breakthroughs. With a strong intellectual property portfolio and collaborations with premier research institutions, Candel is strategically positioned to lead transformative developments in oncology, ultimately aiming to improve patient outcomes and redefine standard care in cancer therapy.
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
Headquarters117 KENDRICK STREET, NEEDHAM, MA, UNITED STATES, 02494
CADL operates in the [sector] and focuses on [industry or core business]. Its primary business involves [main business focus], delivering [specific products or services] to its target market. This specialization allows it to serve [key customers or industries], solidifying its role in the industry.
CADL generates its revenue primarily from [specific revenue sources]. These may include [key products, services, or segments], which contribute a substantial portion to the company’s overall financial performance. Its ability to maintain strong demand in [market or industry focus] is a critical factor in its revenue growth.
CADL operates in the [sector] and the [specific industry]. Its main competitors include [key competitors, if known], which also serve similar markets. Understanding the competitive landscape helps evaluate how CADL differentiates itself through [innovations, cost efficiency, etc.].
Investors should consider risks such as [specific risks like market volatility, regulatory changes, operational challenges, etc.]. Additionally, competition in the [industry] and [external economic factors] could impact CADL's performance. As with any stock investment, assessing these risks is vital for informed decision-making.
As of the latest information, CADL [does/does not] pay a dividend. If dividends are offered, investors should evaluate the payout ratio and company performance to gauge sustainability. Dividends can be a consideration for income-focused investors.
CADL's valuation metrics, such as the price-to-earnings (P/E) ratio or price-to-sales (P/S) ratio, can be compared against industry benchmarks to determine its relative value. Investors often analyze these metrics to assess whether the stock is undervalued, overvalued, or fairly priced within the context of its sector.
CADL has opportunities to grow by [expanding its market share, innovating in key areas, entering new markets, etc.]. Trends such as [specific industry trends] could provide tailwinds for the company. However, success will depend on CADL’s ability to execute its strategy amidst industry challenges.
Investors should track metrics such as revenue growth, profitability, and cash flow to assess CADL’s financial health. Additionally, developments in [specific financial areas] and broader economic conditions are important indicators of future performance and investor interest.
Risk Warning
1.Stock prices may fluctuate significantly; invest with caution. Past performance is not indicative of future results.
2.Digital asset trading involves multiple risks, including market and technical risks. Please make rational decisions and allocate assets wisely.
3.The information contained on this page is for reference only and does not constitute any investment advice.
Transfer
